SOURCE: GeoVax Labs, Inc.

December 10, 2014 14:00 ET

GeoVax's Chief Scientific Officer Invited to Present at Dubai Scientific Conference

ATLANTA, GA--(Marketwired - Dec 10, 2014) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel DNA/MVA platform technology, today announced that its Chief Scientific Officer, Harriet L. Robinson, Ph.D. will participate as an invited speaker at the 8th Dubai International Conference for Medical Sciences to be held on December 15-17, 2014 in Dubai, United Arab Emirates. Dr. Robinson will give two presentations entitled "Working towards an Ebola vaccine" and "Clade B VLP-expressing HIV vaccine."

The Dubai International Conference for Medical Sciences is organized by the Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences which has been established with the main aim of rewarding excellence in research and exemplary service. This year, the themes for the awards and conference are in the fields of Drug Discovery, Vaccines, Cell Therapy and Targeted Therapy. The conference is held as a forum where the winners of the awards and the eminent invited speakers will present reviews of some of their research work. The audience for the conference encompasses scientists, medical doctors, nurses, pharmacists, and students. The talks are expected to target this diverse audience and be of practical interest to the majority.

About GeoVax

GeoVax Labs, Inc. (OTCQB: GOVX) is a biotechnology company developing human vaccines using its novel DNA/MVA vaccine delivery platform. The Company's lead development program is focused on vaccines to prevent, and treat, Human Immunodeficiency Virus (HIV) infections. Recently it has initiated a program to develop an Ebola virus vaccine. GeoVax's unique, two component HIV vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV antibody and anti-HIV T cell immune responses. GeoVax's DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. Priming and boosting can also be done with the MVA. Both the DNA and MVA express the three major proteins of the HIV virus: Gag, Pol, and Env, and produce non-infectious virus-like particles. GeoVax's vaccines are unique in expressing virus-like particles that display the native form of the trimeric membrane-bound HIV-1 envelope glycoprotein. Clinical trials for GeoVax's preventive HIV vaccines have been conducted by the US National Institutes of Health-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID). Overall, GeoVax's vaccines, in various doses and combinations, have been tested in close to 500 humans. GeoVax is using its MVA vaccine platform to develop a vaccine to prevent acquisition of the Ebola virus. Efforts are focused against the current epidemic version of the virus. For more information, go to

Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent HIV or Ebola infection in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

Contact Information